血清miR-21、miR-148b、miR-200a、miR-200b在原发性肝癌患者中的表达及临床诊断意义

目的研究原发性肝癌(HCC)患者血清中微小RNA(miR)-21、miR-148b、miR-200a、miR-200b的表达及临床诊断意义。方法应用实时荧光定量逆转录-聚合酶链反应(qRT-PCR)检测西南医科大学附属医院收治的93例HCC患者(病例组)、48例肝脏良性病变(良性组)、48例慢性肝病患者(慢性肝病组)和50例健康体检者(对照组)血清中miR-21、miR-148b、miR-200a、miR-200b的表达。统计学分析各指标与临床病理特征之间的关系,受试者工作特征(ROC)曲线分析各指标的诊断价值。结果病例组血清miR-21与miR-200b表达显著高于良性组、慢性肝病组及对照组(均P<0.05),miR-200a与miR-148b表达显著低于良性组、慢性肝病组及对照组(均P<0.05)。HCC患者血清miR-21与miR-200b表达与病理分期、病理分级及肿瘤直径有关(均P<0.05),与性别、年龄、有无肝硬化及乙型肝炎病毒(HBV)抗原是否阳性无关(均P>0.05)。血清miR-200a与miR-148b表达与病理分期、病理分级有关(均P<0.05),与性别、年龄、肿瘤直径、有无肝硬化及HBV抗原是否阳性无关(均P>0.05)。miR-21、miR-148b、miR-200a、miR-200b及四项指标联合的ROC曲线下面积(AUC)分别为0.821、0.668、0.772、0.734、0.922。联合诊断的敏感性和特异性均高于任一单一指标。结论HCC患者血清miR-21与miR-200b表达上调,而miR-200a与miR-148b表达下调。并且其表达与病理分期、病理分级有关,联合检测血清miR-21、miR-148b、miR-200a、miR-200b有希望成为新的诊断HCC的肿瘤标志物。     

难治性哮喘患者血浆中miR-21和miR-126的表达及意义

目的 探讨miR-21和miR-126在难治性哮喘及完全控制性哮喘患者血浆中的表达水平和意义.方法 采用实时荧光定量PCR法检测miR-21和miR-126在28例难治性哮喘及完全控制性哮喘患者血浆中的表达水平.结果 难治性哮喘患者血浆中miR-21和miR-126的表达水平均显著高于完全控制性哮喘患者,差异均有统计学意义(t=29.300、3.667,P值均＜0.01).结论 miR-21和miR-126在难治性哮喘患者血浆中的表达均高于完全控制性哮喘患者,miR-21和miR-126的表达水平可能与难治性哮喘有关,且调控可能参与了支气管哮喘发生过程.     

慢性乙型肝炎患者血清miR-21和miR-148b水平变化及其预测肝组织炎症分级和纤维化分期价值探讨*

目的 探讨应用血清miR-21和miR-148b水平预测慢性乙型肝炎(CHB)患者肝组织病理学病变的价值。方法 2016年7月～2021年6月我院诊治的CHB患者134例,行快速肝穿刺活检,评估肝组织炎症活动度分级(G)和肝纤维化分期(S)。采用实时定量逆转录PCR法检测血清miR-21和miR-148b水平。应用受试者工作特征曲线(ROC)下面积(AUC)评估血清miR-21和miR-148b水平评估CHB患者肝组织炎症分级和纤维化分期的效能。结果 经肝组织检查,在134例CHB患者中,发现肝组织炎症活动度分级包括G1级23例、G2级39例、G3级47例和G4级25例,肝纤维化分期包括S1期31例、S2期46例、S3期28例和S4期29例;G1级、G2级、G3级和G4级血清miR-21水平分别为(1.1±0.2)、(1.5±0.3)、(1.8±0.4)和(2.2±0.6),血清miR-148b水平分别为(2.4±0.5)、(2.0±0.3)、(1.6±0.5)和(1.2±0.4),组间差异有统计学意义(P＜0.05);S1期、S2期、S3期和S4期血清miR-21水平分别为(0.9±0.4)、(1.4±0.3)、(1.9±0.5)和(2.7±0.5),血清miR-148b水平分别为(2.8±0.7)、(1.9±0.4)、(1.4±0.4)和(0.9±0.2),组间差异有统计学意义(P＜0.05);分别以血清miR-21=1.5和miR-148b=2.0为截断点,其联合评估肝组织炎症分级大于或等于G2的AUC为0.875,显著高于两项指标单独评估(分别为0.769和0.781,P＜0.05),其灵敏度、特异度和准确度分别为87.0%、82.9%和83.6%;分别以血清miR-21=1.4和miR-148b=1.9为截断点,其联合评估肝纤维化分期大于或等于S2的AUC为0.898,显著高于两项指标单独评估(分别为0.782和0.770,P＜0.05),其灵敏度、特异度和准确度分别为87.1%、73.8%和76.9%。结论 利用CHB患者血清miR-21高水平和miR-148b低水平的特点可以用于评估肝组织炎症分级和肝纤维化分期,值得深入研究。     

心肌特异性miR-133a与cTnT早期诊断急性心肌梗死的价值

目的 比较血循环中心肌特异性miR-133a与肌钙蛋白T（cTnT）在急性心肌梗死（AMI）早期诊断中的价值.方法 收集67例AMI患者和32名非AMI对照者的血浆标本,通过定量逆转录聚合酶链反应（qRT-PCR）测定血浆中miR-133a水平,同时通过电化学发光法检测血浆cTnT的变化.结果 AMI患者血浆中miR-133a水平较非AMI对照者明显升高（P〈0.01）,而当这些AMI患者康复出院时miR-133a水平已回落到基线.MiR-133a水平的波动与研究对象的自身特征无相关性（P＆gt;0.05）.受试者工作特征曲线（ROC）分析表明,miR-133a在早期诊断AMI方面具有显著的心肌特异性和敏感性,但并不优于cTnT.结论 血浆miR-133a可作为AMI早期诊断的标志物,但在诊断价值上并不优于cTnT.     

胰腺癌组织c-MET表达与循环miR-34a、miR-449水平的相关性

目的 探讨胰腺癌组织织间质表皮转化因子(c-MET)的表达与循环miR-34a、miR-449水平的相关性及其临床意义。方法 收集2015年3月至2017年3月间嘉兴医学院附属第二医院行手术治疗并经病理证实的41例胰腺癌患者的临床资料。通过免疫组织化学染色检测胰腺癌组织及其匹配的癌旁正常胰腺组c-MET表达,根据测定结果将患者分为c-MET阳性组与c-MET阴性组。采集患者手术前和手术后3个月外周血,应用荧光定量PCR法检测循环miR-34a和miR-449水平。分析癌组织c-MET表达与患者临床病理参数、预后及循环miR-34a、miR-449水平的关系。分析循环miR-34a和miR-449水平对胰腺癌TNM分期、淋巴结转移和预后的评估价值。结果 胰腺癌组织c-MET阳性率明显高于癌旁正常组织(63.4%比24.4%),差异有统计学意义(P<0.05)。与c-MET阴性患者比较,c-MET阳性患者TNMⅢ/Ⅳ期者居多(73.1%比33.4%),淋巴结转移率高(76.9%比46.7%),生存时间短(29.5个月比35.0个月),生存率低(38.5%比53.3%),差异均有统计学意义(P值均<0.05)。术前c-MET阳性患者循环miR-34a、miR-449水平明显低于c-MET阴性患者(0.228±0.068比0.524±0.106、0.252±0.063比0.432±0.094,P<0.05),术后c-MET阳性患者循环miR-449水平仍明显低于c-MET阴性患者(0.414±0.088比0.512±0.114,P<0.05),但两组间miR-34a水平的差异无统计学意义。术前循环miR-34a、miR-449水平对胰腺癌TNM分期、淋巴结转移及预后有预测价值(P<0.05)。结论 miR-34a、miR-449靶向结合胰腺癌组织c-MET,有可能成为潜在的胰腺癌标志物。     

Down-Regulation of PTEN Expression Modulated by Dysregulated miR-21 Contributes to the Progression of Esophageal Cancer

Background and Aim

miR-21, a putative tumor oncomiR, is a frequently overexpressed miRNA in a variety of tumors. Because it targets tumor-suppressor genes it has been linked to tumor progression. In this study we investigated the role of miR-21 in esophageal squamous cell carcinoma (ESCC), and its possible mechanism.

Methods

Expression of miR-21 was detected by stem–loop RT-PCR in tissue from 76 invasive ESCC at stage I–IV and in their corresponding para-cancerous histological normal tissues (PCHNT). Thirty endoscopic esophageal mucosal biopsy specimens from non-tumor patients were used as controls. Expression of PTEN in 76 paired ESCC and PCHNT was investigated by real-time RT-PCR and an immunohistochemical method, respectively. Paired tumor and PCHNT specimens of 20 ESCC cases were randomly selected for western blot analysis. The effect of miR-21 on PTEN expression was assessed in the ESCC cell line with an miR-21 inhibitor to reduce miR-21 expression. Furthermore, the roles of miR-21 in cell biology were analyzed by use of miR-21 inhibitor-transfected cells.

Results

Stem–loop RT-PCR revealed miR-21 was significantly overexpressed in ESCC tissues and cell lines. Overexpression of miR-21 correlated with tumor status, lymph node metastasis, and clinical stage. We demonstrated that knockdown of miR-21 significantly increased expression of PTEN protein. Consequent PTEN expression reduced cell proliferation, invasion, and migration.

Conclusions

Our findings suggest that miR-21 could be a potential oncomiR, probably by regulation of PTEN, and a novel prognostic factor for ESCC patients.     

Micro RNA-1290 promotes esophageal squamous cell carcinoma cell proliferation and metastasis

AIM:To investigate the biological role of mi R-1290 in esophageal squamous cell carcinoma(ESCC) progression and invasion and the underlying mechanism.METHODS:Quantitative real-time polymerase chain reaction(q RT-PCR) was performed to evaluate mi R-1290 expression in ESCC tissue samples.The roles of mi R-1290 in cell proliferation,migration and invasion were identified using mi R-1290 mimic-transfected cells.In addition,the regulatory effect of mi R-1290 on suppressor of cancer cell invasion(SCAI) was evaluated using q RT-PCR,Western blot analysis and a dual luciferase reporter assay.RESULTS:mi R-1290 was significantly upregulated in ESCC tissue samples compared with normal adjacent tissues(9.213 ± 1.150 vs 1.000 ± 0.0),(P 0.01).Upregulation of mi R-1290 was associated with tumor differentiation(P = 0.021),N classification(P = 0.006) and tumor-node-metastasis stage(P = 0.021) in ESCC patients.Moreover,ectopic mi R-1290 expression potently promoted ESCC cell growth(P 0.01),migration(P 0.01) and invasion(P 0.01) in vitro.mi R-1290 overexpression in ESCC cell lines decreased SCAI expression at the translational level and reduced SCAI-driven luciferase-reporter activity(P 0.01).CONCLUSION:Our findings suggested that mi R-1290 may play an oncogenic role in cellular processes of ESCC.     

急性ST段抬高型心肌梗死患者血浆微小核糖核酸-208a水平对并发急性心力衰竭的预测价值

目的:探讨血清微小核糖核酸-208a(miR-208a)表达水平对急性ST段抬高型心肌梗死(STEMI)患者并发急性心力衰竭的预测关系。方法:连续性收集2018年1月至2019年6月,就诊于我科的152例急性STEMI患者纳入病例组,并随机选择同期在我院行健康体检的志愿者60例为对照组。根据发病48 h内是否发生急性心力衰竭(AHF)将病例组分为AHF亚组和非AHF亚组。采用实时荧光定量PCR(RT-qPCR)法检测血浆miR-208a的相对表达水平。结果:病例组血浆miR-208a相对表达水平显著高于对照组(Z=10.919,P=0.000)。AHF亚组血浆miR-208a相对表达水平显著高于非AHF亚组(Z=9.573,P=0.000)。Pearson相关性分析结果显示,病例组患者血浆miR-208a相对表达水平与BNP、hsCRP和cTnI均呈正相关关系(r=0.612,P=0.000;r=0.447,P=0.000;r=0.378,P=0.000)。二分类Logistic回归分析结果显示血浆miR-208a相对表达水平是急性STEMI患者并发AHF的危险因素(OR=2.118,95%CI 1.127~3.982,P=0.007)。血浆miR-208a预测AHF的AUC为0.896(0.844,0.948),cut-off值为32.00,对应的敏感性和特异性分别为88.4%和83.3%。结论:急性STEMI患者血浆miR-208a表达水平显著升高,且可能是并发AHF的危险因素。     

Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report

Decreased plasma levels of microRNA-223 (miR-223), predominantly of platelet origin, were proposed as a surrogate marker of efficacy of antiplatelet therapy. However, higher on-treatment platelet reactivity was associated with lower plasma miR-223 in patients with coronary artery disease (CAD) on dual antiplatelet therapy (DAPT) including clopidogrel and aspirin. Our aim was to compare plasma miR-223 and platelet reactivity in CAD patients on DAPT with newer P2Y₁₂ antagonists vs. clopidogrel. We studied 21 men with CAD admitted to our centre owing to a non-ST-elevation acute coronary syndrome, and with an uncomplicated hospital course. From the day of admission, the patients were receiving either clopidogrel (n?=?11) or prasugrel/ticagrelor (n?=?10) in addition to aspirin. Before discharge, miR-223 expression in plasma was estimated by quantitative polymerase chain reaction using the comparative Ct method relative to miR-16 as an endogenous control. Multiple electrode aggregometry was used to assess platelet aggregation in response to adenosine diphosphate (ADP). ADP-induced platelet reactivity was decreased in the patients treated with prasugrel or ticagrelor compared with those on clopidogrel (mean?±?SD: 139?±?71 vs. 313?±?162 arbitrary units [AU]*min, p?=?0.006), due to a more potent antiplatelet activity of the novel P2Y₁₂ antagonists. Consequently, six out of seven patients in the lower tertile of the ADP-induced platelet aggregation were treated with the newer P2Y₁₂ blockers, whereas six out of seven patients in the upper tertile were on clopidogrel. Plasma miR-223 was elevated with decreasing platelet reactivity (Spearman’s rho?=?–0.52; p?=?0.015 for trend), being significantly higher in the lower tertile of the ADP-induced platelet aggregation (median [range]: 1.06 [0.25–2.31]) vs. the upper tertile (0.20 [0.13–2.30]) (p?=?0.04). In conclusion, our preliminary results argue against the notion of low plasma miR-223 as a marker of platelet responsiveness to DAPT. On the contrary, more potent platelet inhibition associated mainly with newer P2Y₁₂ antagonists appears to coincide with higher miR-223 relative to the subjects with attenuated responsiveness to DAPT.     

NSCLC患者血清miR-181a的表达变化及其与铂类药物化疗敏感性的关系

目的观察微小RNA（miR）-181a在早期非小细胞肺癌（NSCLC）患者血清中的表达变化,并分析其与铂类药物化疗效果的相关性。方法采用茎环结构的逆转录实时定量PCR方法,检测40例早期NSCLC患者（NSCLC组）术前及其中30例铂类药物化疗前后血清miR-181a水平,同时设40例健康体检者为对照组;分析血清miR-181a水平与NSCLC临床病理特征及铂类药物化疗效果的关系。结果NSCLC组术前和对照组血清miR-181a表达量分别为0．00259、0．00729（P〈0．0001）,前者与肿瘤临床病理特征问无统计学相关性（P均〉0．05）;NSCLC组30例患者化疗前后血清miR-181a相对表达量分别为0．00279、0．00625（P=0．0001）,其中化疗无效、有效者分别为0．00456、0．00793,化疗无效者显著低于化疗有效者及对照组（P分别为0．015、0．005）,后两者比较无显著差异（P=0．806）。结论miR-181a在早期NSCLC患者血清中的水平降低,并与铂类药物化疗敏感性相关;可能作为潜在的生物标记物用于NSCLC的早期诊断及化疗敏感性预测。     

miR-191在胃癌组织中的表达及其靶基因的预测

目的:分析胃癌组织中miR-191的表达及预测其靶基因,并检测靶基因在胃癌组织中的表达.方法:胃癌及配对癌旁正常组织标本50例,应用基于SYBRGreenⅠ的实时荧光定量PCR(qRT-PCR)检测miR-191的表达情况,后用2-??CT方法进行相对定量分析.利用生物信息学软件对miR-191进行靶基因预测.用免疫组织化学检测靶基因在胃癌组织中的表达情况,并分析其与miR-191表达情况的关系.结果:miR-191在胃癌组织中的表达显著高于癌旁正常组织[0.0314(0.0037-0.4924)vs0.0240(0.0037-0.1593),P<0.05],miR-191与临床病理特征(性别、年龄、病理组织分型、淋巴结转移和TNM分期)无显著相关性.对miR-191预测得到磷脂酶C-delta1(phospholipaseC-delta1,PLCD1)、SOX4等9个靶基因,其中SOX4和NDST1被证明是miR-191的靶基因.PLCD1在胃癌组织中的表达显著低于癌旁正常组织(56.7%vs96.7%,P<0.01),且其与miR-191在胃癌中的表达呈负相关(90%vs30%,r=-0.639,P<0.01).结论:miR-191在胃癌组织中呈高表达,可能通过调控PLCD1对胃癌的发病起重要作用.     

2型糖尿病患者血清miR-126表达的临床意义

目的探讨2型糖尿病患者外周血血清中miR-126的表达水平及其临床意义。方法采用荧光定量PCR方法检测77例糖代谢异常患者血清miR-126的表达(其中糖调节受损组26例,初发2型糖尿病组23例,2型糖尿病伴有血管病变患者28例,和30例健康对照组)。结果 miR-126在健康对照组与糖调节受损组血清中的表达无统计学意义(P>0.05);初发糖尿病组与健康对照组及糖调节受损组之间均有统计学意义(P<0.01);糖尿病伴有血管病变组与健康对照组及糖调节受损组之间均有统计学意义(P<0.01),但与初发糖尿病组无统计学意义(P>0.05)。结论 2型糖尿病及合并有血管病变患者外周血血清中miR-126水平呈低表达。     

胸腺素β4在老年晚期非小细胞肺癌中的表达及其对化疗疗效的影响

目的:探讨胸腺素β4(Tβ4)在老年晚期非小细胞肺癌(NSCLC)中的表达与临床病理学因素及一线含铂类化疗疗效的关系。方法:选取94例晚期的老年NSCLC患者病理组织标本,采用免疫组化的方法检测Tβ4的表达水平,分析临床病理特征,采用实体瘤客观疗效评价标准(RECIST)评价化疗效果,进行生存随访。分析Tβ4的阳性表达与无进展生存期(PFS)及总生存期(OS)的关系。结果:在94例老年晚期NSCLC患者中,Tβ4的高表达率为39.4%(37例/94例)。相关性分析表明,Tβ4的高表达与性别、分化程度、病理类型、TNM分期、化疗方案及T分期等因素无关(P<0.05),与化疗疗效(r=0.327,P=0.001)、PFS(r=0.387,P=0.002)及OS(r=0.404,P=0.001)显著相关。多因素Logistic回归分析表明,Tβ4表达为NSCLC患者疗效的影响因素(P<0.05)。COX多因素分析表明Tβ4表达水平是化疗反应率及PFS的预测因素(P<0.05)。结论:Tβ4的高表达与老年晚期NSCLC一线含铂化疗疗效及生存期相关。Tβ4对于老年晚期NSCLC一线含铂化疗方案的疗效预测具有一定的临床意义。     

Expression of circulating microRNA-20a and let-7a in esophageal squamous cell carcinoma

AIM: To investigate the expressions of microRNA-20a (miR-20a) and let-7a in esophageal squamous cell carcinoma (ESCC) and their diagnostic value.METHODS: Seventy patients with ESCC and 40 healthy subjects were enrolled to investigate the expression of miR-20a and let-7a using quantitative real-time PCR. The expression of miR-20a and let-7a was compared between ESCC patients and healthy subjects. The plasma levels of miR-20a and let-7a in relation to patient clinicopathologic parameters, the receiver operating characteristic (ROC) curve, and the sensitivity and specificity of miR-20a and let-7a in ESCC diagnosis were analyzed.RESULTS: Plasma levels of miR-20a were significantly higher in ESCC patients than in healthy controls, and plasma levels of let-7 were lower in ESCC patients than in healthy controls (both P < 0.05). The area under the ROC curve of miR-20a was 0.767 (95%CI: 0.677-0.857; P < 0.001), when the cut-off value was set at 4.77, the sensitivity and specificity were 64.3% and 75.0%, respectively. The area under the ROC curve of let-7a was 0.829 (95%CI: 0.754-0.904; P < 0.001), when the cut-off value was set at 6.22, the sensitivity and specificity were 74.3% and 85.0%, respectively. Thus, the sensitivity and specificity of let-7a were higher than those of miR-20a. The median relative plasma expression of let-7a in clinical stage III/IV (0.24) was lower than that in stage I/II (0.42), while the expression of miR-20a according to stage was not statistically different. The expressions of miR-20a and let-7a were not related to gender, age, tumor diameter, tumor grade, or pathologic stage.CONCLUSION: Plasma miR-20a and let-7a levels are significantly altered in patients with ESCC and can be used as potential biomarkers in the diagnosis of ESCC.     

胃癌患者血清miR-515-3p水平与临床病理特征及预后的关系

目的 探讨胃癌患者血清miR-515-3 p水平与临床病理特征及预后的关系.方法 选择2013年1月至2015年1月在成都医学院第一附属医院接受胃癌手术治疗的130例原发性胃癌患者作为原发性胃癌组,另选择同期在该院进行体检的100名健康志愿者作为正常对照组.分析两组的血清miR-515-3 p水平差异,以及原发性胃癌患...     

Downregulation of microRNA-382 is associated with poor outcome of esophageal squamous cell carcinoma

AIM: To study the potential prognostic role of microRNA-382(miR-382) in esophageal squamous cell carcinoma(ESCC).METHODS: Forty six patients were divided into 2groups according to postoperative survival time:the poor outcome group(28 patients), who showed early metastasis but no recurrence, and died within 1year after surgery, 12 patients of the group received postoperative chemotherapy treatment that was given after early metastasis happening; the good outcome group(18 patients), who had no clinical metastasis and recurrence, and survived 5 years or more after surgery, all patients did not receive any postoperative treatment. Total RNA was extracted from the patients' formalin-fixed and paraffin-embedded esophageal cancer tissues. miR-382 level was evaluated using highthroughput real-time quantitative polymerase chain reaction analysis. The correlation between miR-382 level and clinicopathologic features was analyzed through COX regression model, and Kaplan-Meier analysis was used to analyze the relationship betweenmiR-382 level and patient survival time.RESULTS: miR-382 was differentially expressed in the two groups. Overall the average miR-382 level in the ESCC patients with good outcome was 9.8 ± 3.8,while miR-382 level in the ESCC patients with poor outcome was 3.0 ± 0.8. The differences of miR-382 levels between two groups were significant(P 0.05).Kaplan-Meier analysis results showed that miR-382 expression level generally had a significant reversecorrelation with ESCC patient survival time(P 0.001), in which the patients with higher expressions of miR-382 had a longer survival time either among individuals with the same tumor stage or among the overall patients.CONCLUSION: miR-382 levels are reverse-correlated with ESCC poor outcomes, suggesting that miR-382 could be a potential predictive biomarker for both prognosis and treatment of ESCC.     

斑点追踪超声心动图联合血浆miR-30a评估急性冠状动脉综合征患者近期预后的临床研究

目的探讨斑点追踪超声心动图(STE)联合血浆miR-30a评估急性冠状动脉综合征(ACS)患者近期预后的效能,为指导临床治疗提供参考。方法选择2020年1月至2020年12月在华南理工大学附属第六医院收治的ACS患者252例,均对病变冠脉行完全血运重建。根据患者起病1个月后的预后情况将其分为预后良好组(199例)和预后不良组(53例)。应用STE检测左心室整体纵向应变(LV-GLS)和左心室射血分数(LVEF)。应用real-time PCR法检测血浆miR-30a水平。采用多因素logistic回归分析LV-GLS和血浆miR-30a指标对ACS患者近期预后的影响,采用ROC曲线法分析LV-GLS和血浆miR-30a指标评估ACS患者近期预后的效能。结果预后良好组LV-GLS低于预后不良组,血浆miR-30a相对表达量低于预后不良组,差异有统计学意义(P <0.05),但两组LVEF指标比较差异无统计学意义(P> 0.05)。Pearson相关分析结果显示,ACS患者LV-GLS与血浆miR-30a水平呈正相关(r=0.418,P=0.000)。多因素logistic回归...     

原发骨淋巴瘤42例临床分析

目的探讨原发骨淋巴瘤(PBL)的临床特点及预后。方法入选西京医院2006年至2014年期间收治的PBL患者42例,男24例,女18例,中位年龄45.6(11~78)岁,收集患者的临床资料,包括性别、年龄、有无全身症状、发病部位、临床分期、病理类型、治疗方案、疗效评价等,进行回顾性分析,通过电话和门诊随访至2015年3月。结果 42例患者均以病变部位疼痛或牵涉性麻木为首发临床表现。病理分型均为非霍奇金淋巴瘤(NHL),50%(21/42)为弥漫大B细胞淋巴瘤(DLBCL)。其中17例患者接受了治疗,5例放化疗联合,12例单纯化疗,两组比较,近期疗效差异无统计学意义(P0.05)。4个疗程后评估近期疗效,年龄、性别、分期、乳酸脱氢酶(LDH)水平、有无全身症状、病理分型、美国东部肿瘤协作组(ECOG)评分、国际预后指数(IPI)评分、是否应用利妥昔单抗治疗、是否联合放疗等对完全缓解率(CR)的影响无统计学意义(P0.05)。中位随访时间13(2~48)个月,无进展生存期3年的4例患者中3例应用了利妥昔单抗。结论 42例PBL患者病理类型主要为DLBCL,治疗以化疗为主,联合放疗未明显提高疗效,应用利妥昔单抗可能会改善预后,尚需扩大样本量进行研究。